FAAH and prostate cancer: Moreover, 50 was previouslyfound to be a HSL inhibitor with a reported IC50 valueof 14 nM.180 The three inhibitors weretested in competitive ABPP with lysates of prostate cancer LNCaP andVCaP cells (both expressing FAAH) and PC3 cells (not expressing FAAH).Predictably, compounds 51 and 52 selectivelyblocked ABHD11, differently from 50 which confirmed itsactivity on FAAH in LNCaP and VCaP cells.